论文部分内容阅读
目的 we design the study aiming at detecting the pharmacokinetic difference among gefitinib,icotinib,erlotinib,and OSI-420,themain metabolite of erlotinib,in brain,CSF(cerebrospinal fluid)and plasma,besides,the preliminary efficacy of those three EGFRTKISwas assessed.